These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33145728)

  • 1. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
    Lee YM; Oh MH; Go JH; Han K; Choi SY
    Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer.
    Müller M; Güth U; Varga Z; Reeve K; Bjelic-Radisic V; Fleisch M; Tausch CJ; Elfgen C
    Anticancer Res; 2020 Apr; 40(4):2125-2131. PubMed ID: 32234905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular stratification within triple-negative breast cancer subtypes.
    Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
    Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
    Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
    ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
    Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
    Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
    Burstein MD; Tsimelzon A; Poage GM; Covington KR; Contreras A; Fuqua SA; Savage MI; Osborne CK; Hilsenbeck SG; Chang JC; Mills GB; Lau CC; Brown PH
    Clin Cancer Res; 2015 Apr; 21(7):1688-98. PubMed ID: 25208879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Bareche Y; Venet D; Ignatiadis M; Aftimos P; Piccart M; Rothe F; Sotiriou C
    Ann Oncol; 2018 Apr; 29(4):895-902. PubMed ID: 29365031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
    Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
    Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
    Harano K; Wang Y; Lim B; Seitz RS; Morris SW; Bailey DB; Hout DR; Skelton RL; Ring BZ; Masuda H; Rao AUK; Laere SV; Bertucci F; Woodward WA; Reuben JM; Krishnamurthy S; Ueno NT
    PLoS One; 2018; 13(10):e0204513. PubMed ID: 30312311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
    Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
    Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes.
    Yoo TK; Kang J; Lee A; Chae BJ
    Breast Cancer Res Treat; 2022 Feb; 191(3):599-610. PubMed ID: 35018542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
    Elfgen C; Varga Z; Reeve K; Moskovszky L; Bjelic-Radisic V; Tausch C; Güth U
    Breast Cancer Res Treat; 2019 Aug; 177(1):67-75. PubMed ID: 31154578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in molecular features of triple-negative breast cancers based on the age at diagnosis.
    Gulbahce HE; Bernard PS; Weltzien EK; Factor RE; Kushi LH; Caan BJ; Sweeney C
    Cancer; 2018 Dec; 124(24):4676-4684. PubMed ID: 30311638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.
    Bando Y; Kobayashi T; Miyakami Y; Sumida S; Kakimoto T; Saijo Y; Uehara H
    J Med Invest; 2021; 68(3.4):213-219. PubMed ID: 34759133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
    Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
    Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Clin Breast Cancer; 2018 Oct; 18(5):e1123-e1132. PubMed ID: 29754847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
    Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
    Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.